Study ID: EAY131
This is a precision medicine treatment trial for patients with advanced solid tumors, lymphomas, or myeloma. The study is assessing the effectiveness of medications that individually target tumors that have a particular genetic change.
Please note that the primary MATCH trial (known as the master screening protocol) has closed, but you may still qualify to participate in one of the sub-studies. Your physician would work with a private laboratory for the testing.
Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma.
Please note that the primary master screening protocol for MATCH has closed, but your patients may still qualify to participate in the sub-studies. You would submit assays to a private laboratory (e.g., Caris or Foundation) for the testing.
- Patients with metastatic, locally recurrent unresectable disease who have progressed on at least on SOC line of therapy or rare tumors with no SOC; all solid tumors and lymphomas eligible. Tissue submitted by med onc via SOC to Foundation or Caris Laboratories to determine if the patient's tumor has an aMOI (actionable mutation of interest) for which a MATCH treatment subprotocol (outlined below) may be available
Additional criteria may apply.
|Subprotocol A||EGFR del 19 or L858R mutations||Phase II trial of afatinib in patients with solid tumors (other than small cell and non-small cell lung cancer) or lymphomas, who have activating mutations of EGFR and have progressed after standard treatment||Afatinib 40mg PO QD|
|Subprotocol C1||MET amplification||Crizotinib in patients with tumors with MET amplification||Crizotinib 250mg PO BID|
|Subprotocol C2||MET exon 14 deletion||Crizotinib in patients with tumors with MET exon 14 deletion||Crizotinib 250mg PO BID|
|Subprotocol E||EGFR mutations||AZD9291 in patients with tumors having EGFR T790M mutations (except non-small cell lung cancer) or rare activating mutations of EGFR||AZD9291 - 80mg mg orally daily continuously|
|Subprotocol F||ALK translocations||Crizotinib in patients with tumors (other than adenocarcinoma of lung or ALCL) with ALK translocations||Crizotinib 250mg PO BID|
|Subprotocol G||ROS1 translocation or inversion||Phase II study of dabrafenib and trametinib in patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)||Crizotinib 250mg PO BID|
|Subprotocol H||BRAF V600E or V600K mutations||Phase II study of dabrafenib and trametinib in patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)||Trametinib 2mg orally QD in combo w/Dabrafenib 150mg orally BID|
|Subprotocol J||HER2 amplification||Trastuzumab and pertuzumab (HP) in patients with non-breast, non-gastric/GEJ cancers with HER2 amplification||Trastuzumab and Pertuzumab (HP) IV every 3 weeks|
|Subprotocol L||mTOR mutations||Phase II study of MLN0128 (TAK-228) in patients with tumors with mTOR mutations||MLN0128 (TAK-228) 3mg PO Daily|
|Subprotocol M||TSC1 or TSC2 mutations||Phase II study of MLN0128 (TAK-228) in patients with tumors with TSC1 or TSC2 mutations||MLN0128 (TAK-228) 3 mg PO daily|
|Subprotocol S2||GNAQ or GNA11 mutation||Phase II study of trametinib in patients with tumors with GNAQ or GNA11 mutations||Trametinib 2mg once daily|
|Subprotocol T||SMO or PTCH1 mutation||GDC-0449 (vismodegib) in patients with tumors (except basal cell skin carcinoma) with smoothened (SMO) or patched-1 (PTCH1) mutations||UpGDC-0449 (vismodegib) 150 mg po daily|
|Subprotocol V||cKIT mutations in exon 9, 11, 13 or 14||Phase II Study of sunitinib in patients with tumors with cKIT mutations (excluding GIST, renal cell carcinoma or pancreatic neuroendocrine tumor)||Sunitinib 50mg PO daily x28 days with 14 days rest|
|Subprotocol W||FGFR pathway mutation||AZD4547 in patients with tumors with aberrations in the FGFR pathway (FGFR1-3 amplification, mutation, or translocation)||AZD4547, 80mg PO BID|
|Subprotocol Z1C||CDK4 or CDK6 amplification and Rb protein expression by IHC||Phase II study of palbociclib (PD-0332991) in patients with tumors with CDK4 or CDK6 amplification and Rb protein expression by IHC||Palbociclib 125mg by mouth daily on days 1-21 on a 28-day cycle|
|Subprotocol Z1E||NTRK fusions||LOXO-101 in patients with tumors with NTRK fusions||LOXO-101 100 mg PO BID|
|Subprotocol Z1I||BRCA1 and BRCA2 mutations||Phase II study of AZD1775 in patients with tumors containing BRCA1 and BRCA2 mutations||AZD1775, 300mg PO daily for 5 days on 2 days off, 2 weeks on 1 week off, every 21-day cycle|
- Must have solid tumor or lymphoma that has progressed after having received at least one line of standard treatment (e.g., surgery, chemotherapy, radiation therapy) or must have a tumor or lymphoma for which there is no agreed-upon treatment approach
- Must have tumor that can be biopsied by image-guided or direct vision biopsy, and must be willing and able to undergo a tumor biopsy for molecular profiling
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before entering the study, for the entire time while participating in the study, and for four months after completion of study
Additional criteria may apply. View study arms on the 'for clinicians' tab above for details.